Jeffrey D. Greenberg

7.3k total citations
144 papers, 5.4k citations indexed

About

Jeffrey D. Greenberg is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, Jeffrey D. Greenberg has authored 144 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Rheumatology, 34 papers in Immunology and 31 papers in Genetics. Recurrent topics in Jeffrey D. Greenberg's work include Rheumatoid Arthritis Research and Therapies (108 papers), Systemic Lupus Erythematosus Research (49 papers) and Chronic Lymphocytic Leukemia Research (30 papers). Jeffrey D. Greenberg is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (108 papers), Systemic Lupus Erythematosus Research (49 papers) and Chronic Lymphocytic Leukemia Research (30 papers). Jeffrey D. Greenberg collaborates with scholars based in United States, Canada and Japan. Jeffrey D. Greenberg's co-authors include Joel M. Kremer, George Reed, Jeffrey R. Curtis, Daniel H. Solomon, Leslie R. Harrold, Marc C. Hochberg, Michael E. Farkouh, Peter Tsao, Philip J. Mease and Vibeke Strand and has published in prestigious journals such as Journal of the American College of Cardiology, PLoS ONE and CHEST Journal.

In The Last Decade

Jeffrey D. Greenberg

142 papers receiving 5.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey D. Greenberg United States	41	4.0k	1.5k	1.3k	587	529	144	5.4k
Carl Turesson Sweden	45	4.6k 1.2×	1.2k 0.8×	907 0.7×	593 1.0×	702 1.3×	170	6.6k
Xavier Le Loët France	42	3.3k 0.8×	1.4k 0.9×	1.3k 1.0×	644 1.1×	617 1.2×	198	5.4k
Alejandro Balsa Spain	43	3.3k 0.8×	2.4k 1.5×	920 0.7×	596 1.0×	474 0.9×	285	6.1k
Elisa Gremese Italy	35	2.2k 0.6×	1.2k 0.8×	718 0.5×	306 0.5×	506 1.0×	243	4.2k
Alexandre E. Voskuyl Netherlands	50	5.6k 1.4×	2.2k 1.4×	1.2k 0.9×	713 1.2×	1.6k 3.0×	246	9.2k
Thomas Barnetche France	37	1.9k 0.5×	1.8k 1.1×	626 0.5×	262 0.4×	415 0.8×	124	4.6k
Wietske Kievit Netherlands	38	1.7k 0.4×	1.1k 0.7×	640 0.5×	413 0.7×	585 1.1×	171	4.1k
Marissa Lassere Australia	38	4.2k 1.1×	833 0.5×	1.2k 0.9×	185 0.3×	401 0.8×	122	5.9k
Paco M J Welsing Netherlands	35	2.6k 0.7×	777 0.5×	752 0.6×	393 0.7×	405 0.8×	174	4.2k
Andrew J.K. Östör United Kingdom	31	1.9k 0.5×	982 0.6×	898 0.7×	345 0.6×	390 0.7×	131	3.8k

Countries citing papers authored by Jeffrey D. Greenberg

Since Specialization

Citations

This map shows the geographic impact of Jeffrey D. Greenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey D. Greenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey D. Greenberg more than expected).

Fields of papers citing papers by Jeffrey D. Greenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey D. Greenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey D. Greenberg. The network helps show where Jeffrey D. Greenberg may publish in the future.

Co-authorship network of co-authors of Jeffrey D. Greenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey D. Greenberg. A scholar is included among the top collaborators of Jeffrey D. Greenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey D. Greenberg. Jeffrey D. Greenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kremer, Joel M., Clifton O. Bingham, Laura C. Cappelli, et al.. (2021). Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry. ACR Open Rheumatology. 3(3). 173–184. 105 indexed citations

Johansson, Fredrik, Jamie E. Collins, Vincent Yau, et al.. (2021). Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-world Data Analysis Using Machine Learning. The Journal of Rheumatology. 48(9). 1364–1370. 21 indexed citations

Merola, Joseph F., Lourdes M. Pérez-Chada, Michael Siegel, et al.. (2020). The National Psoriasis Foundation psoriasis treatment targets in real‐world patients: prevalence and association with patient‐reported outcomes in the Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology. 34(9). 2051–2058. 6 indexed citations

Curtis, Jeffrey R., J. Lynn Palmer, George Reed, et al.. (2020). Real‐World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care & Research. 73(8). 1114–1124. 11 indexed citations

Lillegraven, Siri, Jeffrey D. Greenberg, George Reed, et al.. (2019). Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS ONE. 14(1). e0210459–e0210459. 39 indexed citations

Mease, Philip J., Neil A. Accortt, Sabrina Rebello, et al.. (2019). Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting. Rheumatology International. 39(9). 1547–1558. 8 indexed citations

Kavanaugh, Arthur, Rakesh Singh, Chitra Karki, et al.. (2018). Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. Clinical Rheumatology. 37(8). 2275–2280. 6 indexed citations

Mease, Philip J., et al.. (2017). Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis : Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Data Archiving and Networked Services (DANS). 69. 1 indexed citations

Mease, Philip J., Chitra Karki, Jacqueline B. Palmer, et al.. (2017). Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry. The Journal of Rheumatology. 44(8). 1151–1158. 19 indexed citations

10.

Harrold, Leslie R., Carol J. Etzel, Allan Gibofsky, et al.. (2017). Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskeletal Disorders. 18(1). 108–108. 48 indexed citations

11.

Strober, Bruce, Chitra Karki, Marc A. Mason, et al.. (2017). Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. Journal of the American Academy of Dermatology. 78(2). 323–332. 77 indexed citations

12.

Krathen, Michael, George Reed, Hong Chang, et al.. (2014). A Comparison of the Malignancy Incidence Among Patients With Psoriatic Arthritis and Patients With Rheumatoid Arthritis in a Large US Cohort. Arthritis & Rheumatology. 66(6). 1472–1481. 50 indexed citations

13.

Solomon, Daniel H., Joel M. Kremer, Jeffrey R. Curtis, et al.. (2014). SAT0131 Cumulative Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events. Annals of the Rheumatic Diseases. 73. 637–638. 1 indexed citations

14.

Harrold, Leslie R., George Reed, Joel M. Kremer, et al.. (2013). The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Annals of the Rheumatic Diseases. 74(2). 430–436. 51 indexed citations

15.

Yarwood, Annie, Buhm Han, Soumya Raychaudhuri, et al.. (2013). A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Annals of the Rheumatic Diseases. 74(1). 170–176. 51 indexed citations

16.

Zhang, Jie, Ying Shan, George Reed, et al.. (2011). Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort. Arthritis Care & Research. 63(12). 1672–1679. 42 indexed citations

17.

Lee, Sang Hyuck, Hong Chang, Yusuf Yazıcı, et al.. (2009). Utilization Trends of Tumor Necrosis Factor Inhibitors Among Patients with Rheumatoid Arthritis in a United States Observational Cohort Study. The Journal of Rheumatology. 36(8). 1611–1617. 55 indexed citations

18.

Greenberg, Jeffrey D. & Harry Ostrer. (2007). Predicting response to TNF antagonists in rheumatoid arthritis: the promise of pharmacogenetics research using clinical registries.. PubMed. 65(2). 139–42. 7 indexed citations

19.

Greenberg, Jeffrey D., Clifton O. Bingham, Steven B. Abramson, et al.. (2006). Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Care & Research. 55(4). 543–550. 7 indexed citations

20.

Tseng, Chin‐Lin, Jeffrey D. Greenberg, Drew A. Helmer, et al.. (2004). Dual-system utilization affects regional variation in prevention quality indicators: the case of amputations among veterans with diabetes.. PubMed. 10(11 Pt 2). 886–92. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact